Indo-Turkish Biosimilar Connections Build
More Indian firms appear keen to target the Turkish market for biosimilars. After Dr Reddy's outlined its plans earlier this year, Zydus Cadila has now firmed up an alliance with Turkey's Eczacibasi Ilac Pazarlama AS for biosimilars especially in the oncology segment.
You may also be interested in...
Eczacibasi is in talks to sell its US-based nuclear medicine operation Capintec, in a move that appears to signal an intention by the Turkish healthcare group to focus again on the mainstream pharma sector.
A regular roundup of commercial stories appearing in Scrip's sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.
One dose of AbbVie's blockbuster biologic, Humira (adalimumab), in the US equals around six doses of Zydus Cadila's cut-price biosimilar version in terms of the cost of therapy and the Indian firm's product appears to have triggered interesting shifts both in treatment dynamics and the competitive landscape on the domestic market.